OTCQB:CANSF

WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Retrieved on: 
Monday, May 13, 2024
Partnership, API, Investment, Bank statement, Food, Parkinson's disease, Alzheimer's disease, OTC, WLLW, FY, The Company, Therapy, TSX, Fine chemical

These new expected programs combined with our existing collaborations are expected to drive significant revenue growth during the year," continued Dr. Savile.

Key Points: 
  • These new expected programs combined with our existing collaborations are expected to drive significant revenue growth during the year," continued Dr. Savile.
  • On January 31, 2024, Willow announced a new program with a leading API manufacturer to develop a more sustainable, cost-effective manufacturing route for their largest product sold globally.
  • Willow ended the quarter with approximately $1.6 million in cash as of March 31, 2024.
  • Willow's unaudited consolidated interim financial statements and related management's discussion and analysis ("MD&A") for the quarter ended March 31, 2024, are available on the Company's SEDAR+ profile at www.sedarplus.ca .

WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF

Retrieved on: 
Thursday, March 28, 2024
Partnership, HTP, Prednisolone, Enzyme, DNA, Hydrocortisone, Budesonide, Willow, Fine chemical

Transition of R&D programs to commercial revenue: With multiple R&D programs now complete or nearing completion, the Company anticipates generating first commercial revenues from at least two products as they transition to commercial production.

Key Points: 
  • Transition of R&D programs to commercial revenue: With multiple R&D programs now complete or nearing completion, the Company anticipates generating first commercial revenues from at least two products as they transition to commercial production.
  • Commercial revenue is expected to be potentially milestone, royalty, and ingredient supply revenue.
  • Significant increase in revenues: Full year R&D revenues for 2024 are expected to increase by over 100% compared to 2023.
  • In addition, commercial stage revenue is expected to commence on multiple programs.

WILLOW BIOSCIENCES ANNOUNCES STRATEGIC INVESTMENT FROM KALSEC TO DEVELOP INNOVATIVE NATURAL FOOD INGREDIENTS

Retrieved on: 
Tuesday, February 20, 2024
AB, WLLW, TSX, Toronto Stock Exchange, Warrant, Food, Indian stock exchange, Funding, Acceleration, Legislation, Partnership, Security (finance)

CALGARY, AB, Feb. 20, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, is pleased to announce a strategic investment from Kalsec® Inc. ("Kalsec"), a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry, for the continued development of natural food ingredients.

Key Points: 
  • CALGARY, AB, Feb. 20, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, is pleased to announce a strategic investment from Kalsec® Inc. ("Kalsec"), a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry, for the continued development of natural food ingredients.
  • Proceeds from the Financing will be used for the commercialization and development of the Company's pipeline of products, including natural food ingredients, working capital, and general corporate purposes.
  • "We are delighted to expand our partnership with Kalsec to help bring the best products possible to Kalsec's customers with a keen focus on market-leading innovation and sustainability."
  • If the Milestone is achieved, the Company will issue a press release confirming details of the Additional Investment.

WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS

Retrieved on: 
Tuesday, January 16, 2024
WLLW, TSX, API, Pharmaceutical industry

SUNNYVALE, Calif., Jan. 16, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients, today announced a collaboration with Enterin, Inc. ("Enterin"), a clinical stage biopharmaceutical company pioneering novel treatments that target neurodegenerative and metabolic disorders, to develop new sustainable manufacturing routes to their key intermediates and active pharmaceutical ingredients (APIs).

Key Points: 
  • SUNNYVALE, Calif., Jan. 16, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients, today announced a collaboration with Enterin, Inc. ("Enterin"), a clinical stage biopharmaceutical company pioneering novel treatments that target neurodegenerative and metabolic disorders, to develop new sustainable manufacturing routes to their key intermediates and active pharmaceutical ingredients (APIs).
  • Enterin recognized the need to employ more sustainable methods to manufacture its key development targets at reduced cost and less waste and sought Willow's expertise in developing and scaling biobased processes.
  • The initial program will focus on the feasibility of developing a biobased pathway and, if successful, advance development toward implementation at commercial scale.
  • "If successful, we believe the developed biobased route will be more sustainable, cost effective and ensure access to these potentially life-changing medicines in Enterin's development pipeline."

WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023

Retrieved on: 
Wednesday, January 10, 2024
Budesonide, WLLW, DNA, Partnership, API, Outline, TSX, Acceleration, Enzyme, Hydrocortisone, HTP, UDCA, CDMO, Prednisolone, Growth, Fine chemical

"2023 was a transformative year for Willow with the successful development of our highly valuable BioOxi technology platform which we believe will support significant growth in 2024.

Key Points: 
  • "2023 was a transformative year for Willow with the successful development of our highly valuable BioOxi technology platform which we believe will support significant growth in 2024.
  • We also generated record revenue growth through partnerships and implemented a successful corporate and operational reorganization to support the future growth of Willow," said Dr. Chris Savile, Willow's President & CEO.
  • Record revenues in 2023: Revenues increased approximately 60% to an estimated $1.3 million in 2023.
  • Significant increase in revenues: Full year R&D revenues for 2024 are expected to increase by over 100% compared to 2023.

WILLOW AND LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY ADVANCE DEVELOPMENT PROGRAM TO MANUFACTURE SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS

Retrieved on: 
Thursday, December 7, 2023
R, Willow, WLLW, API, TSX, Willow Garage, Fine chemical

SUNNYVALE, Calif., Dec. 7, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, and a Nasdaq-listed biopharma company are advancing their program to develop precise, concise manufacturing routes to advanced intermediates and high-value active pharmaceutical ingredients.

Key Points: 
  • SUNNYVALE, Calif., Dec. 7, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, and a Nasdaq-listed biopharma company are advancing their program to develop precise, concise manufacturing routes to advanced intermediates and high-value active pharmaceutical ingredients.
  • The parties' phase one feasibility program that applied Willow's BioOxi™ platform exceeded expectations and the partner has now agreed to continue full development toward commercialization, including additional R&D and scale-up work.
  • "We appreciate the trust our partner has in Willow to develop sustainable manufacturing routes to APIs and are delighted to continue to work with them to further develop and supply key advanced intermediates to support their development pipeline," said Dr. Chris Savile, Willow's President & CEO.
  • "This is truly an exciting time for Willow and the BioOxi platform as we rapidly move from R&D to manufacturing and supply in 2024."

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Retrieved on: 
Tuesday, November 14, 2023
UDCA, Research, Commercial, Bank statement, WLLW, Willow Garage, Steroid, API, Partnership, Ursodeoxycholic acid, R, TSX, Patent, Pharmaceutical industry, Fine chemical, Renewable energy, Video game, Willow, Q4

On July 20, 2023, Willow announced our savory food program with Kalsec Inc. progressed past the feasibility stage and into the R&D and scale-up work stage.

Key Points: 
  • On July 20, 2023, Willow announced our savory food program with Kalsec Inc. progressed past the feasibility stage and into the R&D and scale-up work stage.
  • On October 24, 2023, Aurora Cannabis Inc. and Willow announced a confidential settlement resolving the ongoing patent ligation in Canada.
  • Willow ended the quarter with approximately $4.0 million in cash as of September 30, 2023, plus receivables of over $0.6 million.
  • On September 12, 2023, Willow announced an insider led convertible debenture financing, which was closed on October 10, 2023 for gross proceeds of $0.8 million.

WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING

Retrieved on: 
Wednesday, October 11, 2023
TSX, WLLW, Warrant, Finance Secretary (India), AB, Toronto Stock Exchange, Legislation, VWAP, MI, Minority, Acceleration, Offering, Security (finance), Share (finance)

CALGARY, AB, Oct. 10, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announce the completion of its previously announced offering of convertible debenture units of the Company (the "Debenture Units"), on a non-brokered private placement basis, for aggregate proceeds of C$800,000 (the "Offering").

Key Points: 
  • CALGARY, AB, Oct. 10, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announce the completion of its previously announced offering of convertible debenture units of the Company (the "Debenture Units"), on a non-brokered private placement basis, for aggregate proceeds of C$800,000 (the "Offering").
  • The Offering was led by insiders including members of the Board of Directors and members of the senior management team of the Company, who subscribed for a total of C$515,000.
  • Each Debenture Unit consists of one 12% unsecured convertible debenture in the principal amount of C$1,000 (each, a "Convertible Debenture") with a maturity date of October 10, 2026 (the "Maturity Date") and 4,762 common share purchase warrants (each, a "Warrant").
  • The Convertible Debentures are convertible at the holder's option into Shares at any time prior to the earlier of the business day immediately preceding the Maturity Date and the date fixed for redemption of the Convertible Debentures at a conversion price of C$0.105 per Share.

WILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API THROUGH PRECISION FERMENTATION

Retrieved on: 
Tuesday, October 3, 2023
Transfer, Immortalised cell line, GMP, Pharma, Partnership, Technology transfer, TT, API, Health, Fermentation, Active ingredient, Willow Garage, TSX, WLLW, Industrial, Food, Willow, Wellness, Fine chemical

SUNNYVALE, Calif., Oct. 3, 2023 /PRNewswire/ -- Willow Biosciences Inc., ("Willow") (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced execution of a collaboration agreement for a cell line productivity optimization development program for manufacturing a large volume anti-infective Active Pharmaceutical Ingredient ("API") through precision fermentation.

Key Points: 
  • SUNNYVALE, Calif., Oct. 3, 2023 /PRNewswire/ -- Willow Biosciences Inc., ("Willow") (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced execution of a collaboration agreement for a cell line productivity optimization development program for manufacturing a large volume anti-infective Active Pharmaceutical Ingredient ("API") through precision fermentation.
  • Through the partnership, SUANFARMA will have access to Willow's proprietary strain optimization technologies to develop a more cost-effective production process.
  • SUANFARMA has engaged Willow to apply its strain engineering technology platform to enable more cost-effective commercial production of the API at SUANFARMA's manufacturing site.
  • SUANFARMA CDMO offers a comprehensive approach to Technology Transfer, aiming to reduce risks and enhance success within their global project management strategy.

WILLOW ANNOUNCES FILING OF PATENT APPLICATION FOR PROCESS TO PRODUCE CORTICOSTEROIDS AT SIGNFICANTLY REDUCED COST

Retrieved on: 
Wednesday, August 30, 2023
Steroid, TSX, Polyphenol, WLLW, Fine chemical, Pharmaceutical industry, Willow

Coupled with pending patent protection, should it be granted, Willow believes this wholly-owned technology will provide a significant competitive advantage to potential pharmaceutical manufacturing partners.

Key Points: 
  • Coupled with pending patent protection, should it be granted, Willow believes this wholly-owned technology will provide a significant competitive advantage to potential pharmaceutical manufacturing partners.
  • "BioOxi is already unlocking valuable revenue growth opportunities in the near-term particularly with corticosteroids, which we believe will be a large-scale market opportunity.
  • We believe the economic value of a Willow-held patent to manufacture at a demonstrably lower cost than current corticosteroid production represents an exciting opportunity for us and our stakeholders."
  • By leveraging BioOxi, commercial partners can revolutionize the manufacturing process of hydroxylated functional ingredients such as steroids, polyphenols, oxyterpenes, and other ingredients.